Home >> Research Area >>MAPK Signaling>>MEK1/2>> MEK162 (ARRY-162, ARRY-438162)

MEK162 (ARRY-162, ARRY-438162)

MEK1/2 inhibitor,potent and selective CAS# 606143-89-9

MEK162 (ARRY-162, ARRY-438162)

Catalog No. BCC1148----Order now to get a substantial discount!

Product Name & Size Price Stock
MEK162 (ARRY-162, ARRY-438162): 5mg $35 In Stock
MEK162 (ARRY-162, ARRY-438162): 10mg Please Inquire In Stock
MEK162 (ARRY-162, ARRY-438162): 20mg Please Inquire Please Inquire
MEK162 (ARRY-162, ARRY-438162): 50mg Please Inquire Please Inquire
MEK162 (ARRY-162, ARRY-438162): 100mg Please Inquire Please Inquire
MEK162 (ARRY-162, ARRY-438162): 200mg Please Inquire Please Inquire
MEK162 (ARRY-162, ARRY-438162): 500mg Please Inquire Please Inquire
MEK162 (ARRY-162, ARRY-438162): 1000mg Please Inquire Please Inquire
Related Products

Quality Control of MEK162 (ARRY-162, ARRY-438162)

Number of papers citing our products

Chemical structure

MEK162 (ARRY-162, ARRY-438162)

3D structure

Chemical Properties of MEK162 (ARRY-162, ARRY-438162)

Cas No. 606143-89-9 SDF Download SDF
PubChem ID 10288191 Appearance Powder
Formula C17H15BrF2N4O3 M.Wt 441.23
Type of Compound N/A Storage Desiccate at -20°C
Synonyms Binimetinib; ARRY-162; ARRY-438162
Solubility DMSO : 50 mg/mL (113.32 mM; Need ultrasonic)
Chemical Name 6-(4-bromo-2-fluoroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide
SMILES CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO
Standard InChIKey ACWZRVQXLIRSDF-UHFFFAOYSA-N
Standard InChI InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of MEK162 (ARRY-162, ARRY-438162)

DescriptionMEK162 is a potent inhibitor of MEK1/2 with IC50 value of 12 nM.
TargetsMEK1MEK2    
IC5012 nM12 nM    

Protocol

Cell Assay [2]
MCF7 cells infected as indicated are seeded in 12-well plates (2×104). After 24 hours, cells are treated with BEZ235 (100 or 200 nM), BKM120 (0.75 or 1 μM), GDC-0941 (1 μM), or MK2206 (2 μM) alone or in combination with MEK162 (1 μM), BI-D1870 (10 μM), or AZD6244 (1 μM), as indicated in text. Cell numbers are quantified by fixing cells with 4% glutaraldehyde or methanol, washing the cells twice in H2O, and staining the cells with 0.1% crystal violet. The dye is subsequently extracted with 10% acetic acid, and its absorbance is determined (570 nm). Growth curves are performed in triplicate. Viability assays with CellTiter-Glo are performed by plating 2,000 cells in 96-well plates, adding the drug at 24 hours, and assaying 4 to 5 days after drug addition. Cell-cycle and hypodiploid apoptotic cells are quantified by flow cytometry. Briefly, cells are washed with PBS, fixed in cold 70% ethanol, and then stained with propidium iodide while being treated with RNase. Quantitative analysis of sub-G1 cells is carried out in a FACScalibur cytometer using Cell Quest software[2].

Animal Administration [1][2]
Mice[2] Six-week-old female athymic nude Foxn1nu mice are purchased from Harlan Laboratories. Mice are housed in air-filtered laminar flow cabinets with a 12-hour light/12-hour dark cycle and given food and water ad libitum. Mice are handled with aseptic procedures and allowed to acclimatize to local conditions for 1 week before the experimental manipulations. A 17β-estradiol pellet is implanted subcutaneously into each mouse 1 day before cell injection. 107 MCF-GFP or MCF7-RSK4 cells are resuspended in PBS/Matrigel (1:1) and injected subcutaneously into the right flank of each mouse in 200 μL of final volume. Treatments began when tumors reached an average size of 250 mm3 and are thus considered as established growing xenografts. Mice are treated once daily with placebo, BEZ235, BKM120, MK-2206, or MEK162 by oral gavage. BEZ235 (25-30 mg/kg, 6IW [6 days on 1 day off]) and BKM120 (30 mg/kg, 6IW) are dissolved in 10% NMP-90% PEG, freshly formulated, and administrated within 30 minutes. MK-2206 (100 mg/kg, 3IW) is formulated in 30% Captisol and MEK162 (6 mg/kg, BID) in 0.5% Tween-80, 1% carboxymethyl cellulose. For tumor growth studies, mice are treated for 7-24 days, depending on the xenograft model and treatment regime. Tumor xenografts are measured with calipers 3 times a week, and tumor volume is determined using the following formula: (length×width2)×(π/6). At the end of the experiment, the animals are anesthetized with 1.5% isofluorane-air mixture and killed by cervical dislocation. Tumors are removed 2 hours following the last administration. Rats[1] Rat collagen-induced arthritis (CIA) and rat adjuvant-induced arthritis (AIA) models are used to determine efficacy in the subacute inflammation setting. In the CIA studies, rats with established disease, induced by injections of Type II collagen, are treated with 0.3, 1 or 3 mg/kg ARRY-438162 (PO, BID) with or without 30 mg/kg ibuprofen (PO, QD) for six days. Body weight and ankle diameter are used to monitor disease progression on days 0-7. The AIA model is induced by an injection of a lipoidal amine in FCA on day 0. The AIA rats are treated with 1, 3 or 10 mg/kg ARRY-438162 (PO, QD) beginning on day 8 and continuing for 6 days, with or without the addition of 0.05 mg/kg methotrexate (PO, QD) which is dosed days 0-13. Disease progression is monitored on days 7-14 measuring both paw diameter and body weight.

References:
[1]. J Pheneger, et al. 2006, ACR Annual Scientific Meeting. Abst 794. [2]. Serra V, et al. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest, 2013, 123(6), 2551-2563. [3]. Kiessling MK, et al. Mutant HRAS as novel target for MEK and mTOR inhibitors. Oncotarget. 2015 Dec 8;6(39):42183-96. [4]. Cheng H, et al. PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Oncogene. 2016 Jun 9;35(23):2961-70. [5]. Seip K, et al. Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors. Oncotarget. 2016 Apr 12;7(15):19997-20015.

MEK162 (ARRY-162, ARRY-438162) Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

MEK162 (ARRY-162, ARRY-438162) Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of MEK162 (ARRY-162, ARRY-438162)

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.2664 mL 11.332 mL 22.6639 mL 45.3278 mL 56.6598 mL
5 mM 0.4533 mL 2.2664 mL 4.5328 mL 9.0656 mL 11.332 mL
10 mM 0.2266 mL 1.1332 mL 2.2664 mL 4.5328 mL 5.666 mL
50 mM 0.0453 mL 0.2266 mL 0.4533 mL 0.9066 mL 1.1332 mL
100 mM 0.0227 mL 0.1133 mL 0.2266 mL 0.4533 mL 0.5666 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on MEK162 (ARRY-162, ARRY-438162)

MEK162 (ARRY-162, ARRY-438162) is a novel, selective inhibitor of MEK 1/2 with IC50 of about 12 nM [1].

Co-treatment of MEK162 and PKC inhibitors persistently inhibited MAP-kinase pathway. The co-treatment can halt proliferation and induce apoptosis of uveal melanoma cells even with GNAQ or GNA11 mutations [2]. All N-RAS mutant melanoma cells were sensitive to MEK 162. MEK162 reduced ERK1/2 phosphorylation, clonogenic survival, and induced apoptosis [3].

Phase Ib or II clinical trials were conducted in 32 cutaneous melanoma patients. 20 patients in MEK162 monotherapy and 12 on MEK162 plus RAF inhibitor or selective BRAF inhibitor combination therapy underwent ophthalmological examinations and multimodal imaging. These therapy all induced transient retinopathy with multiple bilateral lesions in some patients. The effect of MEK162 in retinopathy has been usually mild, self-limiting, and tolerable [4].

References:
[1]. Jed Pheneger, Eli Wallace, Allison Marlow, Brian Hurley, Joe Lyssikatos, Alison M. Bendele, Patrice A. Lee1. Array BioPharma, Boulder, CO; Bolder BioPath, Boulder, CO. Characterization of ARRY-438162, a potent MEK inhibitor in combination with Methotrexate or Ibuprofen in vivo models of arthritis. American college of rheumatology. 2006 Annual Scientific Meeting.
[2]. Chen X, Wu Q, Tan L, Porter D, Jager MJ, Emery C, Bastian BC. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. Oncogene. 2013 Oct 21.
[3]. Thumar J, Shahbazian D, Aziz SA, Jilaveanu LB, Kluger HM. MEK targeting in N-RAS mutated metastatic melanoma. Mol Cancer. 2014 Mar 4;13:45.
[4]. Urner-Bloch U, Urner M, Stieger P, Galliker N, Winterton N, Zubel A, Moutouh-de Parseval L, Dummer R, Goldinger SM. Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Ann Oncol. 2014 May 26. pii: mdu169.

Featured Products
New Products
 

Description

Binimetinib (MEK162) is an oral and selective MEK1/2 inhibitor. Binimetinib (MEK162) inhibits MEK with an IC50 of 12 nM.

Keywords:

MEK162 (ARRY-162, ARRY-438162),606143-89-9,Binimetinib; ARRY-162; ARRY-438162,Natural Products,MEK1/2, buy MEK162 (ARRY-162, ARRY-438162) , MEK162 (ARRY-162, ARRY-438162) supplier , purchase MEK162 (ARRY-162, ARRY-438162) , MEK162 (ARRY-162, ARRY-438162) cost , MEK162 (ARRY-162, ARRY-438162) manufacturer , order MEK162 (ARRY-162, ARRY-438162) , high purity MEK162 (ARRY-162, ARRY-438162)

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: